Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Sarah A Bendien, Hans A Kroes, Lotte Hg van Hal, Gert-Jan Braunstahl, Marielle Eac Broeders, Karen Tm Oud, Kornelis Wiebe Patberg, Frank Wjm Smeenk, Ilonka Hpaa van Veen, Els Jm Weersink, Karin B Fieten, Simone Hashimoto, Anneke van Veen, Jaap K Sont, Astrid van Huisstede, Marjo Jt van de Ven, Bas Langeveld, Anke-Hilse Maitland-van der Zee, Anneke Ten Brinke
BACKGROUND: Bronchiectasis is a common co-morbidity in patients with asthma and associated with increased disease severity. In patients with severe eosinophilic asthma biologics targeting interleukin (IL)-5/5Ra have shown beneficial effects on oral corticosteroid (OCS) use and exacerbation frequency. However, how coexisting bronchiectasis affects the response to these treatments is unknown. OBJECTIVE: To evaluate the real-world effectiveness of anti-IL-5/5Ra therapy in patients with severe eosinophilic asthma and comorbid bronchiectasis on exacerbation frequency and daily maintenance and cumulative OCS dose...
June 7, 2023: Journal of Allergy and Clinical Immunology in Practice
#22
JOURNAL ARTICLE
Josje Otten, Rik van der Lans, Eugenio de Corso, Kanstantsin Dziadziulia, Bart Hilvering, Els Weersink, Matteo Bonini, Jan Hagemann, Wanrawee Thaitrakool, Claudio Montuori, Ludger Klimek, Sietze Reitsma, Wytske Fokkens
INTRODUCTION: Type 2 targeting biologics have reached the market first for asthma and since 2019 also for CRSwNP. As clear guidelines and predictors for optimal biological choice are missing, patients are sometimes required to switch biologic therapy in order to find the optimal treatment result. In this paper, we evaluate reasons for switching biologics and the treatment effects after each sequential switch. MATERIALS AND METHODS: Ninety-four patients who switched from one biologic to another for their treatment of CRSwNP and asthma were evaluated...
2023: Expert Review of Clinical Immunology
#23
JOURNAL ARTICLE
Jérémy Laroche, Geneviève Pelletier, Marie-Ève Boulay, Andréanne Côté, Krystelle Godbout
INTRODUCTION: Monoclonal antibodies targeting interleukin 5 (IL5) or its receptor (IL5R) are frequently used in severe asthma, in which they reduce exacerbations rate and oral corticosteroids (OCS) exposure. Anti-IL5/IL5Rs have been studied in patients with chronic obstructive pulmonary disease (COPD) without convincing benefits. However, these therapies have been used in clinical practice in COPD with apparently good results. PURPOSE: To describe the clinical characteristics and therapeutic response of COPD patients treated with anti-IL5/IL5R in a real-world setting...
2023: International Journal of Chronic Obstructive Pulmonary Disease
#24
JOURNAL ARTICLE
Stefania Principe, Levi B Richards, Simone Hashimoto, Johannes Anthon Kroes, Job J M H Van Bragt, Susanne J Vijverberg, Jacob K Sont, Nicola Scichilone, Kristina Bieksiene, Anneke Ten Brinke, Zsuzsanna Csoma, Barbro Dahlén, Bilun Gemicioglu, Ineta Grisle, Piotr Kuna, Zorica Lazic, Florin Mihaltan, Sanja Popović-Grle, Sabina Škrgat, Alessandro Marcon, Marco Caminati, Ratko Djukanovic, Celeste Porsbjerg, Anke-Hilse Maitland Van Der Zee
BACKGROUND: The use of anti-interleukin-5 (IL5) for severe asthma is based on criteria from randomised controlled trials (RCTs), but in real-life patients might not fulfil the eligibility criteria but may benefit from biologics. We aimed to characterise patients starting anti-IL5(R) in Europe and evaluate the discrepancies between initiation of anti-IL5(R) in real life and in RCTs. MATERIALS AND METHODS: We performed a cross-sectional analysis with data from the severe asthma patients at the start of anti-IL5(R) in the Severe Heterogeneous Asthma Research collaboration Patient-centred (SHARP Central) registry...
July 2023: ERJ Open Research
#25
REVIEW
Dorien Van Broeck, Brecht Steelant, Glenis Scadding, Peter W Hellings
Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a clinical syndrome characterized by nasal polyposis, asthma, and intolerance to aspirin/NSAID. It affects approximately 15% cases of severe asthma, 10% of nasal polyps and 9% of rhinosinusitis. N-ERD results in associated asthma exacerbations, oral corticosteroids bursts, corticosteroid-dependent disease, and multiple endoscopic sinus surgeries. Unknown influences cause polyp epithelium to release alarmins, such as IL-33 and TSLP...
2023: Front Allergy
#26
JOURNAL ARTICLE
Julia U Holle, Frank Moosig
Hypereosinophilic syndrome (HES) is defined as a peripheral eosinophil count of > 1500/μl (assessed twice at an interval of ≥ 2 weeks) and an eosinophil-induced organ damage. Idiopathic HES is differentiated from primary (clonal or neoplastic) HES and secondary (reactive) HES, depending on the etiology. Eosinophilic granulomatosis with polyangiitis (EGPA) is categorized as a secondary form of HES and is characterized by hypereosinophilia and vasculitis of small to medium-sized vessels and can be associated with an antineutrophil cytoplasmic antibody (ANCA)...
April 26, 2023: Zeitschrift Für Rheumatologie
#27
Ioannis Kouverianos, Andreas Angelopoulos, Dimitrios Daoussis
Eosinophilic granulomatosis with polyangiitis (EGPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, mostly affecting small-sized arteries and usually occurring in patients with an allergic background. Eosinophils seem to play a significant role in the pathogenesis of the disease and, therefore, biologics targeting interleukin 5 (IL5), a cytokine tightly linked to eosinophils, have emerged as a promising therapeutic tool. A systematic review of Medline was conducted from 2007 to 2022 to search for data regarding the use of anti-IL5 therapies in patients with EGPA...
April 21, 2023: Rheumatology International
#28
JOURNAL ARTICLE
Kentaro Ito, Tomoyoshi Shibuya, Kei Nomura, Mayuko Haraikawa, Taro Kurosawa, Keiichi Haga, Yoichi Akazawa, Takashi Murakami, Osamu Nomura, Mariko Hojo, Takashi Yao, Akihito Nagahara
We experienced a case of treatment-resistant eosinophilic gastrointestinal disease (EGID). The patient, a 46-year-old man, presented with a fever, persistent abdominal pain, and an elevated peripheral eosinophil count. Eosinophil infiltration of the intestinal mucosa was also observed, and EGID was diagnosed. Corticosteroid therapy was initiated, but no improvement was seen. However, after mepolizumab (anti-IL5 antibody) was administered, the patient's disease was controlled. Currently, the indications for mepolizumab are limited to bronchial asthma and paraneoplastic eosinophilic polyangiitis, but the experience herein reported suggests its usefulness in the treatment of EGID...
April 21, 2023: Internal Medicine
#29
JOURNAL ARTICLE
Daniel Laorden, Ester Zamarrón, David Romero, Javier Domínguez-Ortega, Elena Villamañán, Itsaso Losantos, Francisco Gayá, Santiago Quirce, Rodolfo Álvarez-Sala
No abstract text is available yet for this article.
March 21, 2023: Respiratory Medicine
#30
JOURNAL ARTICLE
J L Boechat, B Sousa-Pinto, L Delgado, D Silva
Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.0-2.6% of the population (1) and results in relevant direct and indirect costs. Recently, several randomized controlled trials (RCTs) with Type 2-targeting biologicals (anti-IL4Rα, anti-IL5R, anti-IL5 and anti-IgE) opened a new treatment field for patients refractory to first-line treatments (2,3).
June 1, 2023: Rhinology
#31
JOURNAL ARTICLE
Paul E Pfeffer, Nasloon Ali, Ruth Murray, Charlotte Ulrik, Trung N Tran, Jorge Maspero, Matthew Peters, George C Christoff, Mohsen Sadatsafavi, Carlos A Torres-Duque, Alan Altraja, Lauri Lehtimäki, Nikolaos G Papadopoulos, Sundeep Salvi, Richard W Costello, Breda Cushen, Enrico Heffler, Takashi Iwanaga, Mona Al-Ahmad, Désirée Larenas-Linnemann, Piotr Kuna, João A Fonseca, Riyad Al-Lehebi, Chin Kook Rhee, Luis Perez-de-Llano, Diahn-Warng Perng Steve, Bassam Mahboub, Eileen Wang, Celine Goh, Juntao Lyu, Anthony Newell, Marianna Alacqua, Andrey S Belevskiy, Mohit Bhutani, Leif Bjermer, Unnur Bjornsdottir, Arnaud Bourdin, Anna von Bulow, John Busby, Giorgio Walter Canonica, Borja G Cosio, Del Dorscheid, Mariana Muñoz-Esquerre, J Mark FitzGerald, Esther Garcia Gil, Peter G Gibson, Liam G Heaney, Mark Hew, Ole Hilberg, Flavia Hoyte, David J Jackson, Mariko Siyue Koh, Hsin-Kuo Ko Bruce, Jae Ha Lee, Sverre Lehmann, Cláudia Chaves Loureiro, Dóra Lúðvíksdóttir, Andrew N Menzies-Gow, Patrick Mitchell, Andriana I Papaioannou, Todor A Popov, Celeste M Porsbjerg, Laila Salameh, Concetta Sirena, Camille Taillé, Christian Taube, Yuji Tohda, Michael E Wechsler, David Price
BACKGROUND: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. METHODS: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R...
March 17, 2023: Allergy
#32
JOURNAL ARTICLE
D Laorden, I Hernández, J Domínguez-Ortega, D Romero, R Álvarez-Sala, S Quirce
Background. Mepolizumab, a monoclonal antibody that interacts with IL-5, was the first anti-IL-5 approved for uncontrolled severe eosinophilic asthma. In several randomised, placebo-controlled trials, treatment with mepolizumab has shown a significant improvement in asthma symptoms and the need to use of oral corticosteroids (OCS). Several studies have correlated blood levels of eosinophil cationic protein (ECP) with the degree of eosinophilic inflammation, which could make it an indirect marker of eosinophilic activity...
March 16, 2023: European Annals of Allergy and Clinical Immunology
#33
JOURNAL ARTICLE
A Simon Carney, Peter K Smith
BACKGROUND: International consensus statements now subdivide chronic rhinosinusitis (CRS) into several phenotypes and endotypes, including the presence of polyps (CRSwNP) and eosinophilia (eCRSwNP). Biological treatments aimed at blocking eosinophilic inflammation in CRSwNP via interleukin 5 (IL5) or the interleukin 5 receptor (IL5R) have demonstrated limited efficacy thus far. OBJECTIVE: To review the pathophysiology of eCRSwNP, the evidence for mepolizumab (anti-IL5) and benralizumab (anti-IL5R) in CRSwNP, and to highlight areas for future research and therapeutic intervention...
March 2023: American Journal of Rhinology & Allergy
#34
MULTICENTER STUDY
Angelantonio Maglio, Carolina Vitale, Corrado Pelaia, Maria D'Amato, Luigi Ciampo, Eliana Sferra, Antonio Molino, Giulia Pelaia, Alessandro Vatrella
Add-on biological therapy has proven to be effective in many patients with severe eosinophilic asthma. In this observational multicenter retrospective study, we report the results obtained with mepolizumab and benralizumab in severe asthmatics treated for 12 months in a real-life setting. In these patients, peripheral eosinophil levels, pulmonary function trends, exacerbation rates, systemic corticosteroid use, and symptom control were evaluated during the observation period, to understand which patients met all the criteria in order to be considered in disease remission...
January 27, 2023: International Journal of Molecular Sciences
#35
JOURNAL ARTICLE
Susana Rojo-Tolosa, María Victoria González-Gutiérrez, Gonzalo Jiménez-Gálvez, José Antonio Sánchez-Martínez, Laura Elena Pineda-Lancheros, José María Gálvez-Navas, Alberto Jiménez-Morales, Cristina Pérez-Ramírez, Concepción Morales-García
Severe Uncontrolled Asthma (SUA) counts for more than 25% of cases of severe asthma. The main factors that impair the quality of life of these patients are high doses of oral corticosteroids, the presence of exacerbations, and reduced lung function. The objective of this study was to evaluate, in real life, the clinical improvement of patients with SUA treated with anti-interleukin 5 (IL5) therapies: mepolizumab and benralizumab, together with the search for biomarkers associated with the response. We conducted a retrospective observational cohort study that included patients with severe uncontrolled eosinophilic asthma in a tertiary hospital receiving biological therapies...
January 19, 2023: International Journal of Molecular Sciences
#36
JOURNAL ARTICLE
L Klimek, U Förster-Ruhrmann, H Olze, A G Beule, A M Chaker, J Hagemann, T Huppertz, T K Hoffmann, S Dazert, T Deitmer, S Strieth, H Wrede, W Schlenter, H J Welkoborsky, B Wollenberg, S Becker, F Bärhold, F Klimek, I Casper, J Zuberbier, C Rudack, M Cuevas, C A Hintschich, O Guntinas-Lichius, T Stöver, C Bergmann, P Werminghaus, O Pfaar, J Gosepath, M Gröger, C Beutner, M Laudien, R K Weber, T Hildenbrand, A S Hoffmann, C Bachert
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and sinuses. Eosinophilic inflammation is described as a common endotype. The anti-IL5 antibody mepolizumab was approved in November 2021 as an add-on therapy to intranasal glucocorticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps when systemic glucocorticosteroids or surgery do not provide adequate disease control...
February 2023: Laryngo- Rhino- Otologie
#37
MULTICENTER STUDY
Khalaf Kridin, Marie-Charlotte Brüggen, Sarah Walsh, Benoit Bensaid, Annamari Ranki, Eva Oppel, Damian Meyersburg, Ser-Ling Chua, Corsin Seeli, Heidi Sandberg, Lars E French, Artem Vorobyev, Saskia Ingen-Housz-Oro
BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but potentially fatal drug hypersensitivity reaction. OBJECTIVE: To explore treatment approaches across Europe and their impact on the disease course, as well as prognostic factors and culprit drugs. METHODS: In this retrospective European multicentric study, we included patients with probable or certain DRESS (RegiSCAR score ≥ 4) between January 2016 and December 2020...
April 2023: Journal of the European Academy of Dermatology and Venereology: JEADV
#38
JOURNAL ARTICLE
Sylwia Biały, Milena Iwaszko, Jerzy Świerkot, Bartosz Bugaj, Katarzyna Kolossa, Sławomir Jeka, Katarzyna Bogunia-Kubik
Ankylosing spondylitis (AS) is an inflammatory disease that belongs to the spondyloarthritis family. IL-5 and IL-9 belong to the group of Th2 cytokines of anti-inflammatory nature. Polymorphisms in their coding genes have been so far associated with various inflammatory diseases, but there are no reports regarding their involvement in AS pathogenesis to date. The purpose of the study was to investigate relationships between IL5 and IL9 genetic variants with AS susceptibility, clinical parameters as well as response to therapy with TNF inhibitors...
October 29, 2022: International Journal of Molecular Sciences
#39
JOURNAL ARTICLE
Wenjia Chen, Mohsen Sadatsafavi, Trung N Tran, Ruth B Murray, Chong Boon Nigel Wong, Nasloon Ali, Cono Ariti, Esther Garcia Gil, Anthony Newell, Marianna Alacqua, Mona Al-Ahmad, Alan Altraja, Riyad Al-Lehebi, Mohit Bhutani, Leif Bjermer, Anne Sofie Bjerrum, Arnaud Bourdin, Lakmini Bulathsinhala, Anna von Bülow, John Busby, Giorgio Walter Canonica, Victoria Carter, George C Christoff, Borja G Cosio, Richard W Costello, J Mark FitzGerald, João A Fonseca, Kwang Ha Yoo, Liam G Heaney, Enrico Heffler, Mark Hew, Ole Hilberg, Flavia Hoyte, Takashi Iwanaga, David J Jackson, Rupert C Jones, Mariko Siyue Koh, Piotr Kuna, Désirée Larenas-Linnemann, Sverre Lehmann, Lauri A Lehtimäki, Juntao Lyu, Bassam Mahboub, Jorge Maspero, Andrew N Menzies-Gow, Concetta Sirena, Nikolaos Papadopoulos, Andriana I Papaioannou, Luis Pérez de Llano, Diahn-Warng Perng, Matthew Peters, Paul E Pfeffer, Celeste M Porsbjerg, Todor A Popov, Chin Kook Rhee, Sundeep Salvi, Camille Taillé, Christian Taube, Carlos A Torres-Duque, Charlotte S Ulrik, Seung Won Ra, Eileen Wang, Michael E Wechsler, David B Price
Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of severe asthma patients with HOCS who did and did not initiate biologics. Methods: Baseline characteristics of patients with HOCS (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR; https://isaregistries...
2022: Journal of Asthma and Allergy
#40
JOURNAL ARTICLE
Jan Romantowski, Aleksandra Górska, Grażyna Moszkowska, Julia Kulczycka, Karolina Minkowska, Agata Rolewicz, Marita Nittner-Marszalska, Marek Niedoszytko
(1) Asthma is a chronic inflammatory airway disease. Around 3-10% of patients experience severe refractory asthma. These patients with high symptom intensity and frequent exacerbations present a challenge for allergologists. Their allergic vs. non-allergic profile might be different from the standard asthmatic group and this difference is vital in qualifying for anti-IgE biologicals. The aim of the study was to analyze multiple sensitizations in patients with severe asthma and assess their impact on the course of the disease...
September 29, 2022: Life
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
